



Press Release

Prof. Reinhard Dummer joins Oncobit as Senior Medical Advisor

Zurich, Switzerland - 01.02.2025 - Oncobit AG, a leading Swiss cancer precision medicine company, is pleased to announce that Prof. Reinhard Dummer has joined the company as Senior Medical Advisor, effective February 1, 2025. Prof. Dummer, a globally recognized expert in dermato-oncology, brings decades of clinical and research experience to Oncobit, further strengthening the company's commitment to enabling personalized cancer care.

Prof. Dummer is a highly cited Professor of Dermatology at the University Zurich. He is renowned for his extensive contributions to skin cancer research, particularly in melanoma and non-melanoma skin cancers at the University Hospital Zurich. His expertise in translational research and clinical development has been instrumental in shaping the future of oncology diagnostics and therapies.

"We are honored to welcome Prof. Dummer to Oncobit," said Dr. Claudia Scheckel, CEO of Oncobit. "His vast experience and deep understanding of oncology will be invaluable as we continue to develop innovative solutions that improve patient outcomes."

As Senior Medical Advisor, Prof. Dummer will play a key role in guiding Oncobit's clinical strategies, and fostering collaborations with leading medical institutions and industry partners. "I am excited to join Oncobit in its mission to revolutionize cancer monitoring," said Prof. Dummer. "Accurate and personalized cancer monitoring solutions are critical for improving cancer treatment, and I look forward to contributing to Oncobit's innovative approach."

Oncobit is dedicated to providing clinicians with accurate, real-time data to optimize cancer treatment strategies. Prof. Dummer's appointment marks a significant milestone in the company's ongoing efforts to advance the field of oncology monitoring.

About:

Oncobit, a leading Swiss cancer precision medicine company, has developed a scalable and data-driven cancer monitoring platform based on the quantitative and sensitive detection of cancer markers in liquid biopsies. By focusing on specific cancer markers that are most relevant, Oncobit provides a cost-effective and time-efficient solution for a tight monitoring of the patient's cancer and an optimized therapy management. Oncobit's cloud-based data analysis and interpretation software was trained on healthy and patient data and ensures a robust and standardized reporting of results. With an initial emphasis on melanoma (already regulatory approved under IVDR), Oncobit has generated significant traction including initial commercial contracts in the pharmaceutical and hospital sectors.

Contact:

Oncobit AG
Dr. Claudia Scheckel, CEO, Oncobit
claudia.scheckel@oncobit.com
+41 78 850 07 87
<https://oncobit.com>